AstraZeneca to demonstrate latest scientific breakthroughs in oncology at ASCO 2016
Every year, the most exciting scientific research in oncology takes centre stage at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, USA. This year, AstraZeneca and MedImmune will provide an update on our extensive pipeline, with 73 total abstracts on our research or molecules across immuno-oncology, targeted tumour drivers, and new agents targeting DNA damage response (DDR). Read more at the link below, and continue to check back closer to ASCO for news, data highlights, and the best of on-site science from Chicago.
Page Atlas ID: 988244.011
Date of next review: May 2017